Valuation: Regeneron Pharmaceuticals, Inc.

Market Cap 63.56B 55.8B 51.37B 47.86B 90.27B 6,043B 92.1B 618B 239B 2,966B 239B 233B 10,323B P/E 2026 *
16.2x
P/E 2027 * 13x
Enterprise Value 55.65B 48.86B 44.97B 41.9B 79.03B 5,290B 80.64B 541B 210B 2,597B 209B 204B 9,038B EV / Sales 2026 *
3.5x
EV / Sales 2027 * 3.01x
Free-Float
72.33%
Yield 2026 *
0.63%
Yield 2027 * 0.71%
1 day+0.19%
1 week+0.21%
Current month+0.19%
1 month+4.01%
3 months-19.62%
6 months-19.06%
Current year-19.06%
1 week 622.29
Extreme 622.29
638.76
1 month 594.9
Extreme 594.9
640.82
Current year 591.52
Extreme 591.52
821.11
1 year 532.6
Extreme 532.6
821.11
3 years 476.49
Extreme 476.4869
1,211.2
5 years 476.49
Extreme 476.4869
1,211.2
10 years 271.37
Extreme 271.37
1,211.2
Manager TitleAgeSince
President 66 31/12/2000
Chief Executive Officer 73 07/01/1988
Director of Finance/CFO 55 04/02/2024
Director TitleAgeSince
Chairman 73 08/06/2023
Director/Board Member 85 31/05/1991
Director/Board Member 85 31/05/1991
Date Insider Type Main position Quantity % Market Cap.
04-30Sell

Director

-100 0.0001%
03-31Sell

Director

100 0.0001%
03-01Sell

Director

100 0.0001%
Change 5-day change 1-year change 3-year change Capi.($)
+0.19%+0.21%+16.79%-13.06% 63.56B
+0.95%+1.46%+56.18%+227.40% 55.92B
+0.36%+39.60%+39.60%+39.60% 41.68B
-0.52%+0.08%-50.89%-57.38% 39.12B
-2.93%+5.09%+61.25%-26.37% 30.97B
+3.53%+19.99%+152.70%-40.33% 28.77B
+0.40%+4.93%+65.59%+82.83% 22.74B
+6.66%+11.56%+7.06%+183.00% 17.64B
-0.06%-0.64%+64.17%+122.53% 16.66B
+0.05%+7.44%+74.19%+333.26% 14.6B
Average +0.85%+4.95%+48.66%+85.15% 33.16B
Weighted average by Cap. +0.59%+3.98%+41.99%+64.32%

Financials

2026 *2027 *
Net sales 15.88B 13.94B 12.83B 11.96B 22.55B 1,510B 23.01B 154B 59.81B 741B 59.63B 58.34B 2,579B 17.55B 15.41B 14.19B 13.22B 24.93B 1,669B 25.44B 171B 66.1B 819B 65.9B 64.48B 2,851B
Net income 4.09B 3.59B 3.3B 3.08B 5.81B 389B 5.92B 39.74B 15.4B 191B 15.35B 15.02B 664B 5.13B 4.51B 4.15B 3.87B 7.29B 488B 7.44B 49.9B 19.33B 240B 19.27B 18.86B 834B
Net Debt -7.91B -6.95B -6.4B -5.96B -11.24B -752B -11.47B -76.92B -29.8B -369B -29.71B -29.07B -1,285B -10.69B -9.38B -8.64B -8.05B -15.18B -1,016B -15.48B -104B -40.24B -499B -40.12B -39.25B -1,735B
Logo Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. specializes in research, development, producing, and selling drugs used in treating ophthalmologic and inflammatory diseases and cancers. Net sales break down by type of revenue as follows: - revenues from collaboration agreements (51.1%): collaboration with Sanofi (80.3% of revenues), Bayer (19.4%) and other (0.3%); - revenues from product sales (30%); - revenues from sales of technology licenses and subcontracted research services (4.9%). At the end of 2025, the group had a portfolio of approximately 45 products in clinical development.
Employees
15,343
Date Price Change Volume
01/07/26 US$624.72 +0.19% 1,170,657
30/06/26 US$623.54 -1.31% 820,925
29/06/26 US$631.81 -0.17% 734,528
26/06/26 US$632.90 +2.06% 1,213,634
25/06/26 US$620.14 -0.53% 696,862
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
29
Last Close Price
624.72USD
Average target price
833.31USD
Spread / Average Target
+33.39%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. REGN Stock